MAIA Q3 Loss Narrows 19% to $7.2M; $21.3M Cash Alleviates Going-Concern Doubt
MAIA sits 25% above its 52-week low of $0.87.
Summary
MAIA narrowed its Q3 2026 net loss to $7.18M from $8.90M and ended September with $21.34M in cash, enough for management to say going-concern doubt is reasonably alleviated — though the March offering that funded it raised shares outstanding to 61.7M from 38.6M.
Key Events · Earnings and Guidance · MAIA
-
Q3 Loss Narrows to $7.2M
Net loss fell to $7.18M from $8.90M a year earlier, with R&D down 16% to $5.34M and G&A down 10% to $2.69M.
-
Cash Rises to $21.3M
Cash reached $21.34M at September 30, 2026 versus $8.66M at December 31, 2025, funded largely by the March 2026 offering.
-
Going-Concern Doubt Alleviated
Management states the substantial doubt about continuing as a going concern for at least 12 months is 'reasonably alleviated' based on cost controls and current cash.
-
Dilution From March Offering
Shares outstanding rose to 61,741,946 from 38,624,289 at year-end after selling 22,005,875 shares at $1.50 for ~$33.0M gross.
Analysis · MAIA · Life Sciences
The going-concern overhang that has shadowed this clinical-stage story is now, in management's words, 'reasonably alleviated' — a meaningful shift for a company that had been funding itself through repeated dilutive raises. Driving the change: the third-quarter loss narrowed to $7.18M from $8.90M a year earlier as R&D and G&A spending fell, while the March 2026 raise lifted cash to $21.34M from $8.66M at year-end. The offset is dilution, with shares outstanding rising to 61.7M from 38.6M at December 31, 2025 after the 22.0M-share offering at $1.50. A pending H.C. Wainwright suit seeking $2.31M plus 1.54M warrants over that March offering remains a live overhang, with oral argument on the dismissal motion set for February 11, 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MAIA was trading at $1.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $0.87 to $3.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.